不同抑酸剂治疗Hp感染伴反流性食管炎的临床疗效分析  

Clinical Efficacy of Different Acid Inhibitors in the Treatment of Hp Infection with Reflux Esophagitis

作　　者：张松 任亚丽 高欣 张校 程建国 李旻 徐维田 ZHANG Song;REN Yali;GAO Xin;ZHANG Xiao;CHENG Jianguo;LI Min;XU Weitian(Department of Gas-troenterology,General Hospital of Central Theater Command,Wuhan Hubei 430070,China)

机构地区：[1]中部战区总医院消化内科,湖北武汉430070 [2]武汉科技大学医学部医学院

出　　处：《联勤军事医学》2024年第4期289-292,共4页Military Medicine of Joint Logistics

基　　金：国家自然科学基金项目(82200708);湖北省科技计划项目(2021CFB001)。

摘　　要：目的 比较伏诺拉生四联疗法与传统的雷贝拉唑四联疗法治疗幽门螺杆菌(Helicobacter pylori, Hp)感染伴反流性食管炎(reflux esophagitis, RE)患者的临床疗效及安全性。方法 回顾性分析2023-01~10月在作者单位就诊的265例Hp感染伴RE患者的临床资料。根据治疗方案分为伏诺拉生组(n=102)和雷贝拉唑组(n=163)。比较两组患者的临床基线资料,分析治疗后的Hp根除率,记录胃食管反流病量表(gastroesophageal reflux disease questionnaire, GerdQ)评分,比较临床疗效,并观察不良反应发生情况。结果 两组Hp感染伴RE患者临床基线资料比较差异无统计学意义(P>0.05)。伏诺拉生组患者的Hp根除率显著高于雷贝拉唑组(P<0.05);治疗6周后,伏诺拉生组患者的GerdQ评分明显低于雷贝拉唑组,治疗总有效率显著高于雷贝拉唑组(P均<0.05)。两组Hp感染伴RE患者不良反应发生率比较差异无统计学意义(P>0.05)。结论 伏诺拉生四联疗法可显著提高Hp感染伴RE患者的Hp根除率和RE临床疗效,是一种值得推荐的安全有效治疗方案。Objective To compare the clinical efficacy and safety of vonoprazan quadruple therapy and rabeprazole quadruple therapy in the treatment of Helicobacter pylori(Hp) infection with reflux esophagitis(RE).Methods The clinical data of 265 patients with Hp infection and RE treated in the author′s hospital from January to October 2023 were retrospectively analyzed. According to the therapeutic regimen, the patients were divided into vonoprazan group(n=102) and rabeprazole group(n=163). The clinical baseline data of patients with Hp infection and RE between two groups were compared, the eradication rate of Hp after treatment was analyzed, the gastroesophageal reflux disease questionnaire(GerdQ) score was recorded, the clinical efficacy was compared, and the occurrence of adverse reactions were compared.Results There was no significant difference in clinical baseline data of patients with Hp infection and RE between two groups(P>0.05). The eradication rate of Hp in vonoprazan group was significantly higher than that in rabeprazole group(P<0.05);after 6 weeks of treatments, the GerdQ score of vonoprazan group was significantly lower than that of rabeprazole group, the total effective rate of vonoprazan group was significantly higher than that of rabeprazole group(all P<0.05), and there was no significant difference in the incidence of adverse reactions of patients with Hp infection and RE between the two groups(P>0.05).Conclusion Vonoprazan quadruple therapy can significantly improve the eradication rate of Hp infection with RE and the clinical efficacy of RE, which is a safety and effective therapeutic regimen.

关 键 词：伏诺拉生四联疗法 幽门螺杆菌 反流性食管炎 钾离子竞争性酸阻滞剂 质子泵抑制剂 

分 类 号：R453.2[医药卫生—治疗学] R571[医药卫生—临床医学]